8-K: Kiromic BioPharma Secures $2 Million in Funding Through Convertible Note

Kiromic BioPharma has entered into a $2 million senior secured convertible promissory note agreement with an accredited investor, providing immediate capital and potential future equity conversion.

Summary

• Kiromic BioPharma issued a 25% Senior Secured Convertible Promissory Note for $2 million to an accredited investor on August 1, 2024.
• The note bears a 25% annual interest rate, increasing to 27% upon default, and matures on August 1, 2025.
• The holder can convert the note into common stock starting October 31, 2024, at 90% of the 5-day VWAP prior to conversion, subject to a 19.99% beneficial ownership limit.
• The note is secured by the company's fixtures, equipment, and intellectual property.
• This new note brings the total outstanding principal amount of notes held by the investor to $10.8 million, along with preferred stock holdings.

Sentiment

Score: 4

Explanation: The high interest rate and secured nature of the note suggest a challenging financial situation for the company, despite the positive aspect of securing funding. The potential for dilution through conversion is also a concern.

Positives

• The $2 million in funding provides Kiromic BioPharma with immediate capital.
• The convertible feature of the note allows for potential future equity participation by the investor.
• The company has the option to prepay the note before the maturity date without penalty.
• The funds are earmarked for the continued development of their CAR-T cell therapy and general corporate purposes.

Negatives

• The 25% interest rate on the note is relatively high, indicating a higher cost of capital.
• The interest rate increases to 27% upon default, adding further financial pressure in case of non-payment.
• The company's assets are pledged as collateral, which could be at risk in case of default.
• The conversion of the note could potentially dilute existing shareholders.

Risks

• Failure to make payments on the maturity date could trigger a default and increase the interest rate to 27%.
• The company's assets are pledged as collateral, which could be at risk in case of default.
• The conversion of the note into common stock could dilute existing shareholders.
• The company's ability to repay the note depends on its future financial performance and ability to raise additional capital.

Future Outlook

The company intends to use the proceeds from the note for the continued development of its CAR-T cell therapy and for general corporate purposes, suggesting a focus on research and development and operational needs.

Industry Context

The financing is typical for a biotech company in the development stage, where securing capital through convertible notes is a common practice to fund research and development activities. The high interest rate reflects the risk associated with early-stage biotech investments.

Comparison to Industry Standards

• The 25% interest rate is high compared to standard corporate debt, but is not uncommon for early-stage biotech companies with limited revenue and high risk profiles.
• Convertible notes are a common financing tool for biotech companies, allowing investors to participate in potential upside while providing immediate capital.
• The security interest in the company's assets is a standard practice for secured debt, providing the lender with some protection in case of default.
• Comparable companies in the biotech sector often use similar financing methods, including convertible notes and equity offerings, to fund their operations and research.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• Employees may benefit from the continued funding of the company's operations and research.
• Creditors may be impacted by the company's debt obligations and ability to repay.
• Customers may benefit from the continued development of the company's CAR-T cell therapy.

Next Steps

• The company will use the funds for the continued development of its CAR-T cell therapy and general corporate purposes.
• The company will need to manage its debt obligations and potentially raise additional capital in the future.
• The company will need to monitor the conversion of the note and its impact on the share structure.

Key Dates

Keywords

convertible note, promissory note, secured debt, financing, capital raise, biopharma, CAR-T therapy, equity conversion, intellectual property, VWAP